This inventor holds 4 USPTO granted patents and 20 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Abbott Products Gmbh, Abbvie Inc., Abbvie Pharmaceuticals Gmbh. Active years: 2014-2022.
Location History:
- Sehnde, DE (2014 - 2022)
- Hannover, DE (2022)
Company Filing History:
2 out of 17 
1 out of 826 
1 out of 1 Years Active: 2014-2022
Title: The Innovator Behind Advanced Enzyme Compositions - George Shlieout
Introduction
George Shlieout, an accomplished inventor based in Sehnde, Germany, has made significant contributions to the field of biochemistry. With a portfolio of four patents, he has focused on innovative solutions that aim to enhance the safety and efficacy of enzyme preparations, particularly in pharmaceutical applications.
Latest Patents
Shlieout's recent inventions include groundbreaking advancements in enzyme compositions designed to minimize viral and microbial contamination. This particular invention details an enzyme preparation derived from e-beam irradiated animal tissue, specifically porcine pancreas. It encompasses methods for creating such enzyme preparations, along with pharmaceutical compositions incorporating them, as well as the methodologies for their practical use.
Another noteworthy patent pertains to the manufacturing and application of pancreatin micropellet cores. This process is notable for producing pancreatin micropellets that are largely free of synthetic oils. A key benefit of his invention is the designed enteric coating, which is crafted to deliver pancreatin effectively to the upper portion of the intestine in mammals, ensuring optimal release.
Career Highlights
Throughout his career, George Shlieout has been associated with prominent companies in the healthcare sector, including Abbott Products GmbH and AbbVie Inc. His work in these organizations has allowed him to refine his expertise and contribute to significant advancements in enzyme technology.
Collaborations
In his journey of innovation, Shlieout has collaborated with notable colleagues such as Frithjof Sczesny and Claus-Juergen Koelln. These professional relationships have fostered a collaborative environment that enhances the development of innovative solutions in enzyme applications.
Conclusion
George Shlieout's dedication to advancing enzyme technology positions him as a key player in the field of biochemistry. His innovative patents reflect a commitment to improving pharmaceutical compositions, demonstrating the potential for safer and more effective treatments. As he continues his work, Shlieout is likely to influence the landscape of enzyme applications for years to come.